IKK/NF-κB signaling: Balancing life and death - A new approach to cancer therapy

Journal of Clinical Investigation

Volumn 115, Issue 10, 2005, Pages 2625-2632

  Luo, Jun Li ^a   Kamata, Hideaki ^a   Karin, Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AS 602868; BUTYLATED HYDROXYANISOLE; CYCLOPENTENONE DERIVATIVE; CYTOKINE; DAUNORUBICIN; GLUCOCORTICOID; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTEASOME INHIBITOR; RESVERATROL; SALAZOSULFAPYRIDINE; SN 50; SULINDAC SULFIDE; UNCLASSIFIED DRUG; I KAPPA B;

APOPTOSIS; CANCER; CANCER CELL; CELL DEATH; CELL SURVIVAL; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE INDUCTION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR REGRESSION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 26444605834     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI26322     Document Type: Review

References (119)

1. Ghosh, S., and Karin, M. 2002. Missing pieces in the NF-kappaB puzzle [review]. Cell. 109(Suppl.): S81-S96.
2. Karin, M., and Lin, A. 2002. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:221-227.
3. Karin, M., and Delhase, M. 2000. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 12:85-98.
4. Li, Z.W., et al. 1999. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J. Exp. Med. 189:1839-1845.
5. Senftleben, U., et al. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science. 293:1495-1499.
6. Senftleben, U., and Karin, M. 2002. The IKK/NF-kappa B pathway. Crit. Care Med. 30(1 Suppl.): S18-S26.
7. Bonizzi, G., and Karin, M. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280-288.
8. Varfolomeev, E.E., and Ashkenazi, A. 2004. Tumor necrosis factor: an apoptosis JuNKie [review]? Cell. 116:491-497.
9. Kamata, H., et al. 2005. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell. 120:649-661.
10. Maeda, S., et al. 2003. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity. 19:725-737.
11. Weil, R., and Israel, A. 2004. T-cell-receptor- and B-cell-receptor- mediated activation of NF-kappaB in lymphocytes. Curr. Opin. Immunol. 16:374-381.
12. Hsu, L.C., et al. 2004. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature. 428:341-345.
13. Kerr, J.F., Wyllie, A.H., and Curtie, A.R. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics [review]. Br. J. Cancer. 26:239-257.
14. Wyllie, A.H., Kerr, J.F., and Currie, A.R. 1980. Cell death: the significance of apoptosis [review]. Int. Rev. Cytol. 68:251-306.
15. Danial, N.N., and Korsmeyer, S.J. 2004. Cell death: critical control points. Cell. 116:205-219.
16. Hengartner, M.O. 2000. The biochemistry of apoptosis. Nature. 407:770-776.
17. Leist, M., and Jaattela, M. 2001. Four deaths and a funeral: from caspases to alternative mechanisms [review]. Nat. Rev. Mol. Cell Biol. 2:589-598.
18. Jaattela, M., and Tschopp, J. 2003. Caspase-independent cell death in T lymphocytes. Nat. Immunol. 4:416-423.
19. Abraham, M.C., and Shaharn, S. 2004. Death without caspases, caspases without death. Trends Cell Biol. 14:184-193.
20. Yu, L., et al. 2004. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 304:1500-1502.
21. Kang, T.B., et al. 2004. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173:2976-2984.
22. Fiers, W., Beyaert, R., Declercq, W., and Vandenabeele, P. 1999. More than one way to die: apoptosis, necrosis and reactive oxygen damage [review]. Oncogene. 18:7719-7730.
23. Beg, A.A., Sha, W.C., Bronson, R.T., Ghosh, S., and Baltimore, D. 1995. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 376:167-170.
24. Doi, T.S., et al. 1999. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 96:2994-2999.
25. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K.F., and Verma, I.M. 1999. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science. 284:321-325.
26. Makris, C., et al. 2000. Female mice heterozygous for IKK gamma/NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol. Cell. 5:969-979.
27. Chaisson, M.L., Brooling, J.T., Ladiges, W., Tsai, S., and Fausto, N. 2002. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J. Clin. Invest. 110:193-202. doi:10.1172/JCI200215295.
28. Lavon, I., et al. 2000. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat. Med. 6:573-577.
29. Peter, M.E., and Krammer, P.H. 2003. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10:26-35.
30. Micheau, O., and Tschopp, J. 2003. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:181-190.
31. Kucharczak, J., Simmons, M.J., Fan, Y., and Gelinas, C. 2003. To be, or not to be: NF-kappaB is the answer. Role of Rel/NF-kappaB in the regulation of apoptosis [review]. Oncogene. 22:8961-8982.
32. Scaffidi, C., et al. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1675-1687.
33. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481-490.
34. Li, H., Zhu, H., Xu, C.J., and Yuan, J. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491-501.
35. Zhang, Y., and Chen, F. 2004. Reactive oxygen species (ROS), troublemakers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res. 64:1902-1905.
36. Papa, S., Zazzeroni, F., Pham, G.G., Bubici, C., and Franzoso, G. 2004. Linking JNK signaling to NF-kappaB: a key to survival. J. Cell Sci. 117:5197-5208.
37. Chen, F., Castranova, V., Li, Z., Karin, M., and Shi, X. 2003. Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res. 63:7689-7693.
38. De Smaele, E., et al. 2001. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature. 414:308-313.
39. Tang, G., et al. 2001. Inhibition of JNK activation through NF-kappaB target genes. Nature. 414:313-317.
40. Sakon, S., et al. 2003. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 22:3898-3909.
41. Schwabe, R.F., et al. 2003. c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology. 37:824-832.
42. Yamada, Y., Kirillova, I., Peschon, J.J., and Fausto, N. 1997. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. U. S. A. 94:1441-1446.
43. Papa, S., et al. 2004. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol. 6:146-153.
44. Amanullah, A., et al. 2003. Cell signalling: cell survival and a Gadd45-factor deficiency [comment]. Nature. 424:741; discussion, 742.
45. Kamata, H., and Hirata, H. 1999. Redox regulation of cellular signalling. Cell. Signal. 11:1-14.
46. Salmeen, A., et al. 2003. Redox regulation of protein tyrosine phosphatase 1B involves a sulphenylamide intermediate. Nature. 423:769-773.
47. van Montfort, R.L., Congreve, M., Tisi, D., Carr, R., and Jhoti, H. 2003. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature. 423:773-777.
48. Meng, T.C., Fukada, T., and Tonks, N.K. 2002. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol. Cell. 9:387-399.
49. Meng, T.C., Buckley, D.A., Galic, S., Tiganis, T., and Tonks, N.K. 2004. Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B. J. Biol. Chem. 279:37716-37725.
50. Sasazuki, T., et al. 2004. Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol. Immunol. 41:547-551.
51. Wong, G.H., Ehvell, J.H., Oberley, L.W., and Goeddel, D.V. 1989. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell. 58:923-931.
52. Pham, C.G., et al. 2004. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell. 119:529-542.
53. Cauwels, A., Janssen, B., Waeytens, A., Cuvelier, C., and Brouckaert, P. 2003. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat. Immunol. 4:387-393.
54. Lin, Y., et al. 2004. Tumor necrosis factor-induced nonapoptotic cell death requires receptor-interacting protein-mediated cellular reactive oxygen species accumulation. J. Biol. Chem. 279:10822-10828.
55. Holler, N., et al. 2000. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat. Immunol. 1:489-495.
56. Liu, C.Y., et al. 2003. Broad-spectrum caspase inhibition paradoxically augments cell death in TNF-alpha-stimulated neutrophils. Blood. 101:295-304.
57. Goldstein, J.C., Waterhouse, N.J., Juin, P., Evan, G.I., and Green, D.R. 2000. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat. Cell Biol. 2:156-162.
58. Waterhouse, N.J., et al. 2001. Cytochrome c maintains mitochondrial transmembrane potential and ATP generation after outer mitochondrial membrane permeabilization during the apoptotic process. J. Cell Biol. 153:319-328.
59. Ricci, J.E., et al. 2004. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell. 117:773-786.
60. Ventura, J.J., Cogswell, P., Flavell, R.A., Baldwin, A.S., Jr., and Davis, R.J. 2004. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev. 18:2905-2915.
61. Cardone, M.H., Salvesen, G.S., Widmann, C., Johnson, G., and Frisch, S.M. 1997. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 90:315-323.
62. Tournier, C., et al. 2000. Requirement pf JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 288:870-874.
63. Deng, Y., Ren, X., Yang, L., Lin, Y., and Wu, X. 2003. AJNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell. 115:61-70.
64. Levkau, B., Scatena, M., Giachelli, C.M., Ross, R., and Raines, E.W. 1999. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NF-kappa B loop. Nat. Cell Biol. 1:227-233.
65. Tang, G., Yang, J., Minemoto, Y., and Lin, A. 2001. Blocking caspase-3-mediated proteolysis of IKKbeta suppresses TNF-alpha-induced apoptosis. Mol. Cell. 8:1005-1016.
66. Reuther, J.Y., and Baldwin, A.S., Jr. 1999. Apoptosis promotes a caspase-induced amino-terminal truncation of IkappaBalpha that functions as a stable inhibitor of NF-kappaB. J. Biol. Chem. 274:20664-20670.
67. Toledano, M.B., and Leonard, W.J. 1991. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. U. S. A. 88:4328-4332.
68. Kapahi, P., et al. 2000. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase J. Biol. Chem. 275:36062-36066.
69. Denecker, G., et al. 2001. Death receptor-induced apoptotic and necrotic cell death: differential role of caspases and mitochondria. Cell Death Differ. 8:829-840.
70. Vanden Berghe, T., et al. 2004. Differential signaling to apoptotic and necrotic cell death by Fas-associated death domain protein FADD. J. Biol. Chem. 279:7925-7933.
71. Schmidt-Supprian, M., et al. 2000. NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell. 5:981-992.
72. Bian, X., et al. 2001. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells J. Biol. Chem. 276:48921-48929.
73. Hettmann, T., DiDonato, J., Karin, M., and Leiden, J.M. 1999. An essential role for nuclear factor kappaB in promoting double positive thymocyte apoptosis J. Exp. Med. 189:145-158.
74. Bessho, R., et al. 1994. Pyrrolidine dithiocarbamate, a potent inhibitor of nuclear factor kappa B (NF-kappa B) activation, prevents apoptosis in human promyelocytic leukemia HL-60 cells and thymocytes. Biochem. Pharmacol. 48:1883-1889.
75. Ivanov, V.N., and Ronai, Z. 2000. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene. 19:3003-3012.
76. Campbell, K.J., Rocha, S., and Perkins, N.D. 2004. Active repression of antiapoptotic gene expression by RelA(p6S) NF-kappa B. Mol. Cell. 13:853-865.
77. Webster, G.A., and Perkins, N.D. 1999. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell. Biol. 19:3485-3495.
78. Tergaonkar, V., Pando, M., Vafa, O., Wahl, G., and Verma, I. 2002. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell. 1:493-503.
79. Ryan, K.M., Ernst, M.K., Rice, N.R., and Vousden, K.H. 2000. Role of NF-kappaB in p53-mediated programmed cell death. Nature. 404:892-897.
80. Bohuslav, J., Chen, L.F., Kwon, H., Mu, Y., and Greene, W.C. 2004. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279:26115-26125.
81. Fujioka, S., et al. 2004. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J. Biol. Chem. 279:27549-27559.
82. Egan, L.J., et al. 2004. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc. Natl. Acad. Sci. U. S. A. 101:2452-2457.
83. Benezra, M., et al. 2003. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J. Biol. Chem. 278:26333-26341.
84. Kimura, M., et al. 2003. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 10:718-728.
85. Wiener, Z., et al. 2004. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells. Exp. Cell Res. 299:227-235.
86. Ravi, R., et al. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3:409-416.
87. Driessler, F., Venstrom, K., Sabat, R., Asadullah, K., and Schottelius, A.J. 2004. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin. Exp. Immunol. 135:64-73.
88. Luo, J.L., Maeda, S., Hsu, L.C., Yagita, H., and Karin, M. 2004. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell. 6:297-305.
89. Karin, M., Cao, Y., Greten, F.R., and Li, Z.W. 2002. NF-kappaB in cancer: from innocent bystander to major culprit [review]. Nat. Rev. Cancer. 2:301-310.
90. Lin, A., and Karin, M. 2003. NF-kappaB in cancer: a marked target. Semin. Cancer Biol. 13:107-114.
91. Greten, F.R., and Karin, M. 2004. The IKK/NF-kappaB activation pathway: a target for prevention and treatment of cancer. Cancer Lett. 206:193-199.
92. Gilmore, T.D. 2003. The Rel/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat. Res. 115:241-265.
93. Shishodia, S., and Aggarwal, B.B. 2004. Nuclear factor-kappaB: a friend or a foe in cancer [review]? Biochem. Pharmacol. 68:1071-1080.
94. Perkins, N.D. 2004. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol. 14:64-69.
95. Greten, F.R., et al. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118:285-296.
96. Pikarsky, E., et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466.
97. Becker, C., et al. 2004. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 21:491-501.
98. Seitz, C.S., Lin, Q., Deng, H., and Khavari, P.A. 1998. Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc. Natl. Acad. Sci. U. S. A. 95:2307-2312.
99. van Hogerlinden, M., Rozell, B.L., Ahrlund-Richter, L., and Toftgard, R. 1999. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res. 59:3299-3303.
100. Dajee, M., et al. 2003. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 421:639-643.
101. Zhang, J.Y., Green, C.L., Tao, S., and Khavari, P.A. 2004. NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. Genes Dev. 18:17-22.
102. Seitz, C.S., Freiberg, R.A., Hinata, K., and Khavari, P.A. 2000. NF-κB determines localization and features of cell death in epidermis. J. Clin. Invest. 105:253-260.
103. van Hogerlinden, M., Auer, G., and Toftgard, R. 2002. Inhibition of Rel/nuclear factor-kappaB signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development. Oncogens. 21:4969-4977.
104. Finco, T.S., et al. 1997. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J. Biol. Cbem. 272:24113-24116.
105. Pasparakis, M., et al. 2002. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature. 417:861-866.
106. Moore, R.J., et al. 1999. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med. 5:828-831.
107. Lind, M.H., et al. 2004. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-kappaB inhibition. Proc. Natl. Acad. Sci. U. S. A. 101:4972-4977.
108. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., and Karin, M. 2005. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell. 121:977-990.
109. Monks, N.R., Biswas, D.K., and Pardee, A.B. 2004. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-kappaB as a target [review]. J. Cell. Biochem. 92:646-650.
110. Ravi, R., and Bedi, A. 2004. NF-kappaB in cancer: a friend turned foe. Drug Resist. Updat. 7:53-67.
111. Karin, M., Yamamoto, Y., and Wang, Q.M. 2004. The IKK NF-kappa B system: a treasure trove for drug development [review]. Nat. Rev. Drug Discov. 3:17-26.
112. Orlowski, R.Z., and Baldwin, A.S., Jr. 2002. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 8:385-389.
113. Frelin, C., et al. 2003. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells. Oncogene. 22:8187-8194.
114. Frelin, C., et al. 2005. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 105:804-811.
115. Ziegelbauer, K., et al. 2005. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br. J. Pharmacol. 145:178-192.
116. Niu, C., et al. 1999. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 94:3315-3324.
117. Rousselot, P., et al. 2004. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia. 18:1518-1521.
118. Cavigelli, M., et al. 1996. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 15:6269-6279.
119. Huang, P., Feng, L., Oldham, E.A., Keating, M.J., and Plunkett, W. 2000. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 407:390-395.